Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Rev Med Suisse ; 20(879): 1190-1193, 2024 Jun 19.
Artículo en Francés | MEDLINE | ID: mdl-38898753

RESUMEN

Despite chronic primary pain being recognized as a disease in the 11th revision of the International Classification of Diseases (ICD-11), individuals suffering from it are still too frequently met with a certain skepticism. This skepticism can detrimentally affect their healthcare journey, social life, and economic stability. This article outlines part of the legal evolution regarding the recognition of chronic pain as well as the current insurance-related provisions in Switzerland. With a thorough understanding of this system, physicians can reduce frustration and disputes as well as promoting decision-making processes. The article concludes by highlighting the tools that physicians can use to navigate procedures related to disability insurance effectively.


Malgré une reconnaissance de la douleur chronique primaire comme maladie à part entière dans la 11e révision de la Classification internationale des maladies (CIM), les patient-e-s en souffrant font encore trop fréquemment face à un certain scepticisme. Cela peut leur porter préjudice dans leur parcours de soin, leur vie sociale et leur stabilité économique. Cet article retrace une partie de l'évolution légale de la reconnaissance de la douleur chronique ainsi que les dispositions assécurologiques en vigueur en Suisse. Une bonne connaissance de ce système de la part des médecins peut diminuer la frustration des patient-e-s, les litiges et la lenteur des décisions. Enfin, cet article conclut en proposant des conseils et des outils pour que les médecins puissent accompagner au mieux leurs patient-e-s dans les procédures assécurologiques.


Asunto(s)
Dolor Crónico , Humanos , Dolor Crónico/diagnóstico , Dolor Crónico/psicología , Dolor Crónico/terapia , Suiza , Seguro por Discapacidad , Personas con Discapacidad/psicología , Clasificación Internacional de Enfermedades
2.
Rev Med Suisse ; 20(858): 137-138, 2024 Jan 24.
Artículo en Francés | MEDLINE | ID: mdl-38268357
3.
Heliyon ; 10(15): e34732, 2024 Aug 15.
Artículo en Inglés | MEDLINE | ID: mdl-39157326

RESUMEN

Aim of the study: Complementary and integrative medicine (CIM) has been increasingly recognized as offering promising treatment adjunctions in various clinical settings, even amongst patients with serious, chronic, or recurrent illness. Today, only few tertiary care facilities in Switzerland offer dedicated CIM services for inpatients. The aim of the present study was to evaluate whether CIM services for complex medical conditions are adequately valued by the national inpatient SwissDRG reimbursement system. Methods: A simulation was performed by adding a specific code of the Swiss classification of interventions (CHOP) to the list of codes of each patient who received CIM therapies at the Lausanne University Hospital (CHUV) in 2021. This code is to be used when CIM services are provided. Hitherto, it was not entered due to a lack of specific documents justifying the resources used. The analysis focused on the impact of adding this CIM CHOP code on the Swiss Diagnosis Related Group (DRG) reimbursement. Results: In total, 275 patients received a CIM therapy in 2021. The addition of the CIM CHOP code 99.BC.12 (10-25 CIM sessions per stay) resulted in a simulated loss of income of CHF 766 630 for the hospital, while the net real result is already negative by more than CHF 6 million. The DRGs positively impacted by the addition of CIM CHOP code 99.BC.12 had a mean (SD) cost weight (CW) of 1.014 (0.620), while the DRGs negatively impacted had a mean (SD) CW of 3.97 (2.764) points. Conclusion: It is necessary to quickly react and improve the incentives contained in the grouping algorithm of the prospective payment system, whose effects can threaten the provision of adequate medical care to the patients despite suitable indications and potential for cost-savings.

4.
Brain Behav ; 14(2): e3441, 2024 02.
Artículo en Inglés | MEDLINE | ID: mdl-38409931

RESUMEN

BACKGROUND: The hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD) are connective tissue disorders characterized by generalized joint hypermobility, associated with chronic pain and several symptoms, such as fatigue, dysautonomia, as well as psychiatric co-morbidities. Clinical observations of unusual manifestations during systematic sensory testing raised the question of a possible co-existence with a functional neurological disorder (FND). Hence, this study aimed to assess the presence of positive functional neurological signs (FNS) in a cohort of patients with hEDS/HSD. METHODS: The clinical data of hEDS/HSD patients (N = 24) were retrospectively analyzed and compared to a prospectively recruited age-/sex-matched healthy control group (N = 22). Four motor- and three sensory-positive FNS were assessed. RESULTS: Twenty-two patients (92%) presented at least one motor or sensory FNS. Five patients (21%) presented only a single FNS, 14 presented between 2 and 4 FNS (58%), and 3 patients presented 5 or more FNS (12%). None of the healthy controls presented motor FNS, and only two presented a sensory FNS. CONCLUSIONS: The presence of FNS in hEDS/HSD deserves better clinical detection and formal diagnosis of FND to offer more adequate care in co-morbid situations. In fact, FND can severely interfere with rehabilitation efforts in hEDS/HSD, and FND-targeted physical therapy should perhaps be combined with EDS/HSD-specific approaches.


Asunto(s)
Síndrome de Ehlers-Danlos , Inestabilidad de la Articulación , Neuralgia , Humanos , Estudios Retrospectivos , Síndrome de Ehlers-Danlos/complicaciones , Síndrome de Ehlers-Danlos/diagnóstico , Inestabilidad de la Articulación/complicaciones , Inestabilidad de la Articulación/diagnóstico
5.
Eur J Pain ; 2024 Aug 07.
Artículo en Inglés | MEDLINE | ID: mdl-39113471

RESUMEN

BACKGROUND: Only few previous cohort studies examined simultaneously predictors of chronic pain (CP) onset and recovery. Furthermore, these studies used various sociodemographic and pain-related characteristics, without standardized measures of sleep and depression. The present study aimed at expanding and strengthening these findings in a large Swiss population. METHODS: We analysed data from a longitudinal cohort (n = 4602) collected at two time points separated by 5 years in Lausanne, Switzerland. We studied through two independent multivariable logistic regression models, the predictors of CP onset and recovery, including socio-demographic data as well as standardized measures of sleep and mood. RESULTS: Chronic pain was reported by 43.1% and 44.4% of participants, with 11.6% at the second follow-up reporting moderate or intense pain. Neuropathic pain, regardless of intensity, had a more negative impact on quality of life. An inferential model (n = 1331) identified the male sex as predictive for recovering from CP. Older age, being overweight or obese (compared to normal weight), higher depression scores and pain medication intake were predictive for sustained pain at the second follow-up. A second model (n = 1886) identified being overweight or obese (compared to normal weight), low quality of sleep and being a former smoker (compared to a non-smoker) as predictive for developing CP, while the male sex was lowering the risk. CONCLUSIONS: While sex and weight are associated with both recovery and new CP onset, separate variables also need to be considered in these processes, underlining specific factors to be addressed, depending on the context, whether preventive or therapeutic. SIGNIFICANCE STATEMENT: Multivariable models in a Swiss cohort (N = 4602) associate male sex, not taking pain medication, normal weight, lower depression scores and younger age with recovery from chronic pain, while females, obese or overweight, having worse sleep and former smokers are associated with onset of new chronic pain. These common and separate factors need to be considered in treatment and prevention efforts.

6.
Cancers (Basel) ; 16(9)2024 May 05.
Artículo en Inglés | MEDLINE | ID: mdl-38730736

RESUMEN

BACKGROUND: Awake craniotomy (AC) is recommended for the resection of tumors in eloquent areas. It is traditionally performed under monitored anesthesia care (MAC), which relies on hypnotics and opioids. Hypnosis-assisted AC (HAAC) is an emerging technique that aims to provide psychological support while reducing the need for pharmacological sedation and analgesia. We aimed to compare the characteristics and outcomes of patients who underwent AC under HAAC or MAC. METHODS: We retrospectively analyzed the clinical, anesthetic, surgical, and neuropsychological data of patients who underwent awake surgical resection of eloquent brain tumors under HAAC or MAC. We used Mann-Whitney U tests, Wilcoxon signed-rank tests, and repeated-measures analyses of variance to identify statistically significant differences at the 0.05 level. RESULTS: A total of 22 patients were analyzed, 14 in the HAAC group and 8 in the MAC group. Demographic, radiological, and surgical characteristics as well as postoperative outcomes were similar. Patients in the HAAC group received less remifentanil (p = 0.047) and propofol (p = 0.002), but more dexmedetomidine (p = 0.025). None of them received ketamine as a rescue analgesic. Although patients in the HAAC group experienced higher levels of perioperative pain (p < 0.05), they reported decreasing stress levels (p = 0.04) and greater levels of satisfaction (p = 0.02). CONCLUSION: HAAC is a safe alternative to MAC as it reduces perioperative stress and increases overall satisfaction. Further research is necessary to assess whether hypnosis is clinically beneficial.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA